Use of flutemetamol F-18 is not recommended unless clearly needed.

FDA pregnancy category: C

Animal studies have not been conducted with flutemetamol F-18. There are no controlled data in human pregnancy. All radiopharmaceuticals have the potential to cause fetal harm. The risk of fetal harm is dependent on the stage of fetal development, and the magnitude of the dose. Flutemetamol F-18 should be administered to a pregnant woman only if clearly needed.

FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Avoid use if breastfeeding, or have the mother temporarily interrupt breastfeeding for 24 hours (greater than 10 half-lives of radioactive decay for the F-18 isotope) after exposure to flutemetamol F-18. If breastfeeding is interrupted, the patient should pump and discard her breast milk and use alternate infant nutrition sources (e.g., stored breast milk or infant formula) for 24 hours after administration of the drug.

Breastfeeding is not recommended during use of flutemetamol F-18.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

The effects in the nursing infant are unknown.

See references